Description
MDL 29951 acts as an agonist at GPR17, inhibiting maturation of primary oligodendrocytes and potentially promoting myelin repair in models of multiple sclerosis. MDL 29951 also inhibits NMDA receptors at the glycine site as well as fructose 1,6-bisphosphatase. This compound displays neuromodulatory, anticonvulsant, and antinociceptive activities. In vivo, MDL 29951 inhibits formalin-induced licking. In animal models of seizures, this compound increases thresholds for the development of chemically-induced seizures.
References
Hennen S, Wang H, Peters L, et al. Decoding signaling and function of the orphan G protein-coupled receptor GPR17 with a small-molecule agonist. Sci Signal. 2013 Oct 22;6(298):ra93. PMID: 24150254.
Wright SW, Carlo AA, Danley DE, et al. 3-(2-carboxyethyl)-4,6-dichloro-1H-indole-2-carboxylic acid: an allosteric inhibitor of fructose-1,6-bisphosphatase at the AMP site. Bioorg Med Chem Lett. 2003 Jun 16;13(12):2055-8. PMID: 12781194.
Millan MJ, Seguin L. Chemically-diverse ligands at the glycine B site coupled to N-methyl-D-aspartate (NMDA) receptors selectively block the late phase of formalin-induced pain in mice. Neurosci Lett. 1994 Aug 29;178(1):139-43. PMID: 7816323.
Baron BM, Harrison BL, McDonald IA, et al. Potent indole- and quinoline-containing N-methyl-D-aspartate antagonists acting at the strychnine-insensitive glycine binding site. J Pharmacol Exp Ther. 1992 Sep;262(3):947-56. PMID: 1388205.
